Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Classical hematology 1

Conditions

beta-Thalassemia 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Anemia 2Primary Myelofibrosis 1Higher-risk Myelodysplastic Syndrome 1

Interventions

ruxolitinib 6Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Cytarabine 5fludarabine phosphate 4Whole-Body Irradiation 4Methotrexate 4Daunorubicin 4Thioguanine 3Tacrolimus 3Etoposide 3Early Intervention, Educational 3Cyclophosphamide 3ponatinib 2parsaclisib 2nilotinib 2merphos 2luspatercept 2fludarabine 2fedratinib 2anagrelide 2Tretinoin 2Therapeutics 2Psychiatric Rehabilitation 2Mitoxantrone 2Filgrastim 2Cyclosporins 2Cyclosporine 2Busulfan 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Myeloproliferative Disorders × luspatercept × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡